Overview

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Ciclesonide